Blog Category:

Population-Based Health in Practice: Addressing Health-Related Social Needs

The Centers for Medicare & Medicaid Services (CMS) defines health-related social needs (HRSN) as unmet, adverse social and economic conditions that contribute to a patient’s poor health and affect their ability to maintain well-being. Unemployment, food insecurity, and lack of …

Policies in Practice: Integrating HEDIS and CAHPS Measures into Clinical Care for Medicaid Beneficiaries

The Agency for Healthcare Research and Quality (AHRQ) administers the Consumer Assessment of Healthcare Providers and Systems (CAHPS) program, which creates surveys to evaluate patients’ experiences with ambulatory and facility-level care in commercial and Medicaid plans. The Healthcare Effectiveness Data …

Policies in Practice: Integrating Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) Services into Clinical Care for Medicaid Beneficiaries

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefits provide comprehensive and preventive health care services for children under age 21 who are enrolled in Medicaid. Federal statutes and regulations require that EPSDT preventative, dental, mental, developmental, and specialty services …

Culturally Respectful Care: Integrating Equitable Depression Screening and Linkage to Care in Your Practice

According to the NIH, an estimated 21 million adults experienced at least one major depressive episode in 2020. Clinicians understand that female gender, social isolation, and disturbed family environment increase risk, but may not recognize presenting symptoms of depression in …

Awakening Clinical Competence: Empowering Advanced Practice Providers in the Diagnosis and Management of Narcolepsy and Idiopathic Hypersomnia

Clinicians face considerable hurdles when diagnosing and managing narcolepsy and idiopathic hypersomnia (IH), largely due to overlapping symptoms, insufficient formal training in sleep medicine, and limited recognition of associated psychiatric and cardiometabolic comorbidities. Compounding the challenge, some therapeutic agents—most notably …

Spotting the Red Flags: Screening and Risk Strat Like a Pro

Metabolic dysfunction-associated steatohepatitis (MASH) is a growing clinical challenge due to its increasing prevalence, complex pathophysiology, and strong association with comorbid conditions such as cardiovascular disease and obesity. Evolving diagnostic criteria, risk stratification tools, and new therapeutic options require health …

Individualizing Guideline Concordant Care: T2D and Patients with Multimorbid Conditions

GLP-1 receptor agonists (GLP-1 RAs) are a top-tier recommendation for patients with type 2 diabetes (T2D), especially those with concomitant cardiovascular disease (CVD), chronic kidney disease (CKD), or obesity. Backed by robust clinical trial data and endorsed across leading guidelines, …

Preventing the Preventable: Safe Mycophenolate Practices in Patients of Childbearing Potential

Mycophenolate-containing medications are widely used to prevent organ rejection in transplant recipients and to treat (off label) some autoimmune conditions such as lupus; however, use of these immunosuppressive agents during pregnancy is linked to a significantly increased risk of miscarriage …

GLP-1 RA Myths & Realities: Navigating Safety and Tolerability

GLP-1 receptor agonists (GLP-1 RAs) have redefined the standard of care for type 2 diabetes (T2D), especially in patients with cardiovascular disease (CVD), chronic kidney disease (CKD), obesity, or metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis (MASLD/MASH). These innovative therapies …